Bayer Cropscience India Limited (BAYERCROP) AI Stock Analysis

• Market Cap: ₹253.12B
• Dividend Yield: 2.22%
• Average Volume (3M): 2.47K
• Price to Earnings (P/E): 42.7
• Beta (1Y): 1.01
• Revenue Growth: 15.23%
• EPS Growth: -11.06%
• Country: IN
• Employees: 1,317
• Sector: Basic Materials
• Sector Strength: 60
• Industry: Agricultural Inputs
• EPS (TTM): 62.10
• Shares Outstanding: 44,942,093
• 10 Day Avg. Volume: 3,637
• 30 Day Avg. Volume: 2,471
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹5,873.00
• Price Target Upside: 3.89% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 57 Neutral
• Price Target: ₹5,873.00 ▲(3.89% Upside)

Bayer Cropscience India Limited's overall stock score is primarily influenced by its strong financial position, despite recent challenges in profit margins and cash flow. The technical analysis indicates bearish momentum, which negatively impacts the score. The valuation suggests the stock is overvalued, further weighing down the overall score. The absence of earnings call and corporate events data means these factors do not influence the score.

Bayer Cropscience India Limited Business Overview & Revenue Model

Company Description

Bayer Cropscience India Limited (BAYERCROP) is a leading player in the agriculture sector, focusing on enhancing crop productivity through innovative and sustainable agricultural solutions. The company operates in various segments, including crop protection, seeds, and digital farming. Its core products encompass a broad range of herbicides, fungicides, insecticides, and high-quality seeds designed to help farmers maximize their yields and protect their crops from pests and diseases.

How the Company Makes Money

Bayer Cropscience India Limited generates revenue primarily through the sale of its crop protection products and seeds. The company's key revenue streams include the commercialization of herbicides, fungicides, and insecticides, which are essential for maintaining crop health and ensuring high agricultural productivity. Additionally, Bayer Cropscience India earns income from selling genetically superior seeds that are engineered for higher yields and resilience. The company also invests in digital farming solutions, offering services and tools that provide data-driven insights for better farm management. Strategic partnerships with local distributors and collaborations with agricultural stakeholders further enhance its market reach and revenue potential.

Bayer Cropscience India Limited Financial Statement Overview

Summary

Bayer Cropscience India Limited demonstrates stable revenue growth and a solid balance sheet with low leverage and high equity. Despite a decrease in profit margins and operating cash flow in 2025, robust cash reserves and a healthy capital structure mitigate these risks.

Income Statement

Bayer Cropscience India Limited has shown consistent revenue growth, with Total Revenue increasing from 2020 to 2025. However, gross profit margin declined significantly from 45.36% in 2024 to 28.14% in 2025, indicating rising cost pressures or pricing issues. Net profit margin also decreased from 14.50% in 2024 to 10.38% in 2025. Despite these declines, the company maintains a solid EBIT margin in 2025 at 11.05% and an EBITDA margin of 14.79%, reflecting efficient operations.

Balance Sheet

The balance sheet of Bayer Cropscience India Limited is robust, with a low debt-to-equity ratio of 0.04 in 2025, indicating minimal leverage risk. The equity ratio is strong at 54.35%, showcasing a healthy capital structure. The company also maintains high levels of cash and equivalents, supporting liquidity and stability. Return on Equity (ROE) decreased slightly to 19.92% in 2025, yet remains impressive.

Cash Flow

Cash flow performance is mixed; operating cash flow decreased from 2024 to 2025, which could impact future investments. However, free cash flow generation is stable, and the free cash flow to net income ratio is robust, indicating good cash conversion. Despite the decline in operating cash flow, the company has maintained strong free cash flow growth in prior years.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	52.13B	54.73B	51.03B	51.40B	45.77B	41.43B
Gross Profit	17.41B	15.40B	21.78B	23.24B	18.99B	16.84B
EBITDA	8.04B	8.09B	10.35B	10.91B	9.24B	8.80B
Net Income	5.83B	5.68B	7.41B	7.58B	6.45B	4.93B
Balance Sheet
Total Assets	0.00	52.46B	45.97B	46.79B	43.53B	42.39B
Cash, Cash Equivalents and Short-Term Investments	9.80B	9.29B	12.11B	9.19B	8.19B	12.57B
Total Debt	0.00	1.05B	471.00M	735.00M	864.00M	263.00M
Total Liabilities	-30.82B	23.95B	17.48B	19.66B	18.29B	16.89B
Stockholders Equity	30.82B	28.50B	28.49B	27.12B	25.24B	25.50B
Cash Flow
Free Cash Flow	0.00	2.59B	9.06B	5.32B	1.60B	6.45B
Operating Cash Flow	0.00	3.00B	9.52B	6.09B	2.15B	6.87B
Investing Cash Flow	0.00	389.00M	-300.00M	833.00M	642.00M	67.00M
Financing Cash Flow	0.00	-6.11B	-6.56B	-6.13B	-7.03B	-5.56B

Bayer Cropscience India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5653.30
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAYERCROP, the sentiment is Negative. The current price of 5653.3 is below the 20-day moving average (MA) of 6128.19, below the 50-day MA of 5971.17, and above the 200-day MA of 5447.85, indicating a neutral trend. The MACD of -96.14 indicates Positive momentum. The RSI at 30.45 is Neutral, neither overbought nor oversold. The STOCH value of 10.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BAYERCROP.

Bayer Cropscience India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUMICHEM	70 Outperform	₹296.42B	53.20		0.20%	13.78%	28.22%
COROMANDEL	68 Neutral	₹707.38B	31.26		0.53%	25.15%	54.81%
UPL	68 Neutral	₹581.81B	49.61		0.87%	8.30%	―
PIIND	66 Neutral	₹582.54B	36.15		0.42%	4.07%	-1.28%
CHAMBLFERT	65 Neutral	₹214.77B	12.27		1.86%	0.58%	29.24%
BAYERCROP	57 Neutral	₹253.12B	42.72		2.22%	15.23%	-11.06%
Sector *	44 Neutral	AU$1.54B	-7.28	-26.52%	4.40%	-3.13%	-36.41%